Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.DN-d7ZPu.js ...
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...
The findings suggest that reconsideration of current clinical guidelines, which support MRI only for symptomatic brain ...
The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.
The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.
GlobalData on MSN2d
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancerThe Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...
Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.
After living with metastatic breast cancer for 11 years, I reflect on my journey and plan to embrace the coming year with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback